Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: A pilot study

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Sinha, Sanjeev ^a   Raghunandan, Puroshottam ^a   Chandrashekhar, Rahul ^a   Sharma, Surendra K ^a   Kumar, Sanjiv ^a   Dhooria, Sahajal ^a   Ekka, Meera ^a   Velpandian, Thirumurthy ^a   Ranjan, Sanjay ^a   Ahmad, Hafeez ^a   Samantaray, Jyotish C ^a   Venkatesh, Srinivasaraghavan ^b   Rewari, Bharat B ^b   Khan, Nawaid H ^a   Pandey, Ravindra M ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b Ministry of H and FW Govt of India   (India)

Author keywords

Antiretroviral; Efavirenz; HIV; Nevirapine; Tuberculosis

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RIFAMPICIN; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INDIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PILOT STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; COINFECTION; EPIDEMIOLOGY; HIV INFECTIONS; MICROBIOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; BENZOXAZINES; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED; NEVIRAPINE; PILOT PROJECTS; RIFAMPIN; TUBERCULOSIS;

EID: 84885570685     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-482     Document Type: Article

References (23)

1. Joint United Nations Programme on HIV/AIDS Global report: UNAIDS report on the global AIDS epidemic 2010, Geneva, Available: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/20101123_globalreport_en.pdf., Joint United Nations Programme on HIV/AIDS.
2. World Health Organization Global tuberculosis report 2012 2012, Geneva, Available: http://www.who.int/tb/publications/global_report/en/, World Health Organization.
3. National AIDS Control Organisation India, Department of AIDS Control, Ministry of Health & Family Welfare National AIDS control organization: annual report 2011-12 2013, New Delhi, Available: http://aidsdatahub.org/en/india-reference-library/item/23889-annual-report-2011-12-national-aids-control-organisation-india-department-of-aids-control%20%E2%80%94%20ministry-of-health%20%E2%80%94%20family-welfare-2012, National AIDS Control Organisation India, Department of AIDS Control, Ministry of Health & Family Welfare.
4. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010, Geneva, Available: http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf, World Health Organization.
5. National AIDS Control Organisation, Ministry of Health & Family Welfare, India Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis 2007, New Delhi, Available: http://www.who.int/bulletin/volumes/88/3/09-068759/en/, National AIDS Control Organisation, Ministry of Health & Family Welfare, India.
6. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003, 42:819-850. 10.2165/00003088-200342090-00003, 12882588.
7. Cohen K, Cutsem van G, Boulle A, McIlleron H, Goemaere E, Smith PJ, Maartens G. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in south African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008, 61:389-393.
8. Van Oosterhout JJG, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T, Burger DM, Zijlstra EE. Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians. Antivir Ther 2007, 12:515-521.
9. Manosuthi W, Mankatitham W, Lueangniyomkul A, Chimsuntorn S, Sungkanuparph S. Standard-dose efavirenz vs. Standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin. HIV Med 2008, 9:294-299. 10.1111/j.1468-1293.2008.00563.x, 18400076.
10. Sinha S, Dhooria S, Kumar S, Shah N, Velpandian T, Ravi A, Kumar N, Ahmad H, Bhargwa A, Chug K, Bumma N, Chandrashekhar R, Ekka M, Sreenivas V, Sharma SK, Samantaray J, Mitsuyasu R. The antiretroviral efficacy of highly active antiretroviral therapy and plasma nevirapine concentrations in HIV-TB co-infected Indian patients receiving rifampicin based antituberculosis treatment. AIDS Res Ther 2011, 8:41. 10.1186/1742-6405-8-41, 3223494, 22047185.
11. Van Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Miller S, Gazzard B, Cahn P, Lalloo UG, van der Westhuizen IP, Malan DR, Johnson MA, Santos BR, Mulcahy F, Wood R, Levi GC, Reboredo G, Squires K, Cassetti I, Petit D, Raffi F, Katlama C, Murphy RL, Horban A, Dam JP, Hassink E, van Leeuwen R, Robinson P, Wit FW, Lange JMA, 2NN Study team Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004, 363:1253-1263. 10.1016/S0140-6736(04)15997-7, 15094269, 2NN Study team.
12. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 2010, (12):CD004246. doi:10.1002/ 14651858.CD004246.pub3.
13. World Health Organization, Stop TB Initiative The treatment of tuberculosis guidelines 2010, Geneva, Available: http://www.who.int/tb/features_archive/new_treatment_guidelines_may2010/en/index.html, World Health Organization, Stop TB Initiative.
14. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M, Goemaere E, Coetzee D, Maartens G. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539. 10.1001/jama.300.5.530, 18677025.
15. Varma JK, Nateniyom S, Akksilp S, Mankatittham W, Sirinak C, Sattayawuthipong W, Burapat C, Kittikraisak W, Monkongdee P, Cain KP, Wells CD, Tappero JW. HIV care and treatment factors associated with improved survival during TB treatment in Thailand: an observational study. BMC Infect Dis 2009, 9:42. 10.1186/1471-2334-9-42, 2674442, 19364398.
16. Manosuthi W, Ruxrungtham K, Likanonsakul S, Prasithsirikul W, Inthong Y, Phoorisri T, Sungkanuparph S. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis. Clin Infect Dis 2007, 44:141-144. 10.1086/510078, 17143831.
17. Shipton LK, Wester CW, Stock S, Ndwapi N, Gaolathe T, Thior I, Avalos A, Moffat HJ, Mboya JJ, Widenfelt E, Essex M, Hughes MD, Shapiro RL. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366. 2696339, 19275797.
18. Swaminathan S, Padmapriyadarsini C, Venkatesan P, Narendran G, Ramesh Kumar S, Iliayas S, Menon PA, Selvaraju S, Pooranagangadevi NP, Bhavani PK, Ponnuraja C, Dilip M, Ramachandran R. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011, 53:716-724. 10.1093/cid/cir447, 21890776.
19. Manosuthi W, Sungkanuparph S, Tantanathip P, Lueangniyomkul A, Mankatitham W, Prasithsirskul W, Burapatarawong S, Thongyen S, Likanonsakul S, Thawornwa U, Prommool V, Ruxrungtham K, the NR Study Team A randomized trial comparing plasma drug concentrations and efficacies between 2 Non-nucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N 2 R study. Clin Infect Dis 2009, 48:1752-1759. 10.1086/599114, 19438397, the NR Study Team.
20. Lamorde M, Byakika-Kibwika P, Okaba-Kayom V, Ryan M, Coakley P, Boffito M, Namakula R, Kalemeera F, Colebunders R, Back D, Khoo S, Merry C. Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother 2011, 66:180-183. 10.1093/jac/dkq411, 3001850, 21047828.
21. El-Sadr WM, Perlman DC, Denning E, Matts JP, Cohn DL. A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes. Clin Infect Dis 2001, 32:623-632. 10.1086/318706, 11181127.
22. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010, 50:1288-1299. 10.1086/651686, 20353364.
23. Moses M, Zachariah R, Tayler-Smith K, Misinde D, Foncha C, Manzi M, Bauerfeind A, Mwagomba B, Kwanjana J, Harries AD. Outcomes and safety of concomitant nevirapine and rifampicin treatment under programme conditions in Malawi. Int J Tuberc Lung Dis 2010, 14:197-202.